Helen Shih, MD, MS, MPH, FASTRO, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Helen Shih, MD, MS, MPH, FASTRO, medical director, MGH Proton Therapy Centers; director, CNS & Eye Service; and program Director, Proton Therapy Fellowship, Massachusetts General Hospital, weighs the risks and benefits of treating or postponing treatment of low-grade gliomas.
Transcript
What risks have you seen associated with treating or waiting to treat patients with low-grade gliomas?
It's geography, it's the location. So some parts of the brain are relatively safe to treat, other parts of the brain are near radiation-sensitive structures. And if the radiation dose that's needed to treat a tumor is very close to a radiation-sensitive structure, there's a risk of injuring or impairing the function of something else, such as hearing or vision, or it can just lead to symptoms of like—if we’re treating a larger area or near certain areas—you can have a higher risk of nausea, feeling unwell.
Most of those symptoms during the time of radiation are temporary, thankfully, and do resolve. Even things like hair loss, you know, the hair, the scalp, the hair follicles will determine whether or not hair loss during radiation is going to be temporary or permanent, or something in between. So a lot of it depends on location.
I think another consideration is when you see someone with a low-grade glioma at the first diagnosis, that's the smallest the tumor is ever going to be. Some of the treatments may be able to reduce the density of the tumor and kill off tumor cells, so that there is literally less tumor cells, but the footprint of where the tumor extends to tends to be the same, and then over time it will increase, as it tends to spread beyond the initial volume at time of initial diagnosis. So if you wait on giving radiation treatment, sometimes it's a good thing because you're delaying or avoiding side effects associated with radiation.
But on the flip side, it can also grow beyond the initial volume and then you eventually get radiation. You can actually have more side effects if it's now growing toward, for example, the pituitary gland, which it wasn't at initially, and if that later involves collateral radiation of the pituitary gland, that can cause hormonal or endocrine problems that may not have occurred if you treated the patient first diagnosis.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More